Results were submitted with stained tumor cell percentage and a binary CLDN18.2-positive/negative result for each sample (cut-off: ≥ 75% of tumor cells expressing membranous CLDN18 with ≥ 2+ [moderate to strong] staining intensity). This evidence concerns the gene CLDN18 and neoplasm.